Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MMC · 1 trial · 4 indications
| Arm | Type | Description |
|---|---|---|
| Cohort A2 | EXPERIMENTAL | 120 mg MMC in 90ml gel |
| Cohort B2 | EXPERIMENTAL | 140 mg MMC in 90ml gel |
| Cohort C2 | EXPERIMENTAL | 160 mg MMC in 90ml gel |
| Cohort A | EXPERIMENTAL | 120 mg MMC in 60ml gel |
| Cohort B | EXPERIMENTAL | 140 mg MMC in 60ml gel |
| Cohort C | EXPERIMENTAL | 160 mg MMC in 60ml gel |
| Name | Type | Description |
|---|---|---|
| 120 mg MMC in 90ml gel | DRUG | 120 mg of Mitomycin C mixed with 90 ml UroGen's TC-3 gel |
| 140 mg MMC in 90ml gel | DRUG | 140 mg of Mitomycin C mixed with 90 ml UroGen's TC-3 gel |
| 160 mg MMC in 90ml gel | DRUG | 160 mg of Mitomycin C mixed with 90 ml UroGen's TC-3 gel |
| 120 mg MMC in 60ml gel | DRUG | 120 mg of Mitomycin C mixed with 60 ml UroGen's TC-3 gel |
| 140 mg MMC in 60ml gel | DRUG | 140 mg of Mitomycin C mixed with 60 ml UroGen's TC-3 gel |
| 160 mg MMC in 60ml gel | DRUG | 160 mg of Mitomycin C mixed with 60 ml UroGen's TC-3 gel |
Inclusion Criteria: * Patient is 18 years of age or older. * Patient has signed Informed Consent Form and is willing and able to abide by the protocol. * Patients diagnosed with Low Grade (LG) or High grade (HG) NMIBC. * No active urinary tract infection as confirmed by urine culture. * If the pati...
Top 20 of 51 competitors
MMC in is being studied for non-muscle invasive bladder cancer (NMIBC). It is formulated as a 120 mg dose of mitomycin C in 90 mL of gel and is given intravesically, meaning directly into the bladder, before transurethral resection of bladder tumor (TURBT). It remains investigational and has not been approved for commercial use.
MMC in is being developed by UroGen Pharma Ltd., which trades on the Nasdaq under the ticker URGN. The company is evaluating the drug candidate in patients with non-muscle invasive bladder cancer.
MMC in is in Phase 2 clinical development. The Phase 2 trial has been completed, and the drug is not yet approved for any indication. It remains an investigational therapy.
MMC in has been studied in one completed Phase 2 trial, NCT02307487, titled "Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel and MMC in NMIBC Patients." The trial enrolled 14 participants in Israel and evaluated the drug in bladder cancer and related urinary bladder conditions.